Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Review the current Sarepta Therapeutics Inc (SRPT:XMEX) dividend yield and history to decide if SRPT is the best investment for you.

Learn about the executive team and board of directors at Sarepta Therapeutics Inc (1SRPT:XMIL) and review their bios and compensation over the latest fiscal years.